Related Experiment Video
Updated: Jun 18, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung
Hideyuki Harada1, Nobuyuki Yamamoto, Toshiaki Takahashi
1Division of Radiation Oncology, Shizuoka Cancer Center, Sunto, Shizuoka, Japan.
Background:
The purpose of this study was to retrospectively compare the survival and toxicities associated with chemoradiotherapy using full-dose and weekly regimens in patients with stage III non-small cell lung cancer.
Methods:
Consecutive patients who received concurrent chemoradiotherapy between October 2002 and June 2006 at our institution were enrolled. The prescribed dose for thoracic radiotherapy was 60 Gy in 30 fractions for all the patients.
Results:
Fifty-nine patients were enrolled; 36% of the patients were treated with full-dose regimens and 64% with weekly regimens. The patient characteristics were similar in the two groups. In both univariate and multivariate analyses, treatment with weekly regimens was associated with a better overall survival than that with full-dose regimens (2-year survival rates: 75% for weekly regimens vs 41% for full-dose regimens). The toxicities and compliance in the two groups were comparable.
Conclusion:
Weekly regimens exhibited more favorable overall survival as compared to full-dose regimens in this retrospective study. Confirmation of the results by a randomized phase III trial is warranted.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
